scholarly journals 835P Clinical outcomes of advanced/ recurrent ovarian clear cell carcinoma in a multi-ethnic Asian cohort following bevacizumab and immune checkpoint inhibitor therapy

2020 ◽  
Vol 31 ◽  
pp. S627
Author(s):  
N.Y.L. Ngoi ◽  
A. Lai ◽  
T.Z. Tan ◽  
D.G. Lim ◽  
I.S. Khan ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Clear Cell ◽  
Checkpoint Inhibitor ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma ◽  
Checkpoint Inhibitor Therapy ◽  
Asian Cohort

First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis

2020 ◽  
Vol 16 (2) ◽  
pp. 4341-4345 ◽  
Author(s):  
Ravi B Parikh ◽  
Emily K Feld ◽  
Matthew D Galsky ◽  
Blythe JS Adamson ◽  
Aaron B Cohen ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Urothelial Cell ◽  
Urothelial Cell Carcinoma ◽  
First Line ◽  
The Usa ◽  
Checkpoint Inhibitor Therapy ◽  
Advanced Urothelial Carcinoma

Aim: Standard first-line treatment of advanced urothelial cell carcinoma involves cisplatin-based chemotherapy, with carboplatin or immune checkpoint inhibitor therapy (ICI) reserved for cisplatin-ineligible individuals. Methods: Using a large de-identified electronic health record-derived database of patients with advanced urothelial cell carcinoma in the USA, we examined trends in utilization of first-line systemic therapies in cisplatin-eligible patients from 1 January 2015 to 31 March 2018. Results: Among 1181 cisplatin-eligible patients, the quarterly proportion who received first-line ICI increased from 1 to 42% (ptrend <0.001), while the proportion who received cisplatin-based chemotherapy decreased from 53 to 33% (ptrend = 0.018). Patients receiving ICI were older than those receiving cisplatin (median age: 75 vs 68). Conclusion: Our analysis suggests rising off-label ICI use in cisplatin-eligible individuals, potentially because of ICI’s favorable toxicity profile.

scholarly journals Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0230306 ◽  
Author(s):  
Thomas T. DeLeon ◽  
Daniel R. Almquist ◽  
Benjamin R. Kipp ◽  
Blake T. Langlais ◽  
Aaron Mangold ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Therapy ◽  
Pathogenic Mutations ◽  
Checkpoint Inhibitor Therapy ◽  
Melanoma Patients

scholarly journals Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma

2020 ◽  
Vol 119 (4) ◽  
pp. 793-804 ◽  
Author(s):  
Huei-Jean Huang ◽  
Lan-Yan Yang ◽  
Hsiu-Jung Tung ◽  
Fei-Chun Ku ◽  
Ren-Chin Wu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Ovarian Clear Cell Carcinoma

scholarly journals A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)

2020 ◽  
Vol 30 (8) ◽  
pp. 1239-1242
Author(s):  
Natalie YL Ngoi ◽  
Valerie Heong ◽  
Samuel Ow ◽  
Wen Yee Chay ◽  
Hee Seung Kim ◽  
...  
Keyword(s):  
Sample Size ◽  
Cell Carcinoma ◽  
Disease Progression ◽  
Immune Checkpoint ◽  
Clear Cell ◽  
Clear Cell Carcinoma ◽  
Progression Free Survival ◽  
Oncology Group ◽  
Ovarian Clear Cell Carcinoma ◽  
Free Survival

BackgroundThe optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis in ovarian clear cell carcinoma.Primary objectiveTo evaluate the efficacy of durvalumab (MEDI-4736) compared with standard chemotherapy in patients with recurrent ovarian clear cell carcinoma.Study hypothesisPatients with recurrent ovarian clear cell carcinoma treated with durvalumab will have improved progression-free survival compared with those treated with chemotherapy of physician’s choice.Trial designThe MOCCA study is a multicenter, open-label, randomized phase II trial in patients with recurrent ovarian clear cell carcinoma, which recruited from eight sites across Gynecologic Cancer Group Singapore (GCGS), Korean Gynecologic-Oncology Group (KGOG), and Australia New Zealand Gynecological Oncology Group (ANZGOG). Enrolled patients were randomized in a 2:1 ratio to receive durvalumab or physician’s choice of chemotherapy until disease progression, intolerable toxicity, or withdrawal of patient consent.Major inclusion/exclusion criteriaEligible patients required histologically documented diagnosis of recurrent ovarian clear cell carcinoma, as evidenced by WT1 negativity. All patients must have been of Eastern Cooperative Oncology Group (ECOG) performance status 2 or better, and have had previous treatment with, and progressed or recurred after prior platinum-based chemotherapy. No more than four prior lines of treatment were allowed and prior immune checkpoint inhibitor treatment was not permitted.Primary endpointsThe primary endpoint was the median progression-free survival following treatment with durvalumab, compared with physician’s choice of chemotherapy. Progression-free survival was defined as the time from the first day of treatment to the first observation of disease progression, or death due to any cause, or last follow-up.Sample sizeThe target sample size was 46 patients.Estimated dates for completing accrual and presenting resultsAccrual has been completed and results are expected to be presented by mid-2021.Trial registrationClinicaltrials.gov: NCT03405454.

A Novel Defined Pyroptosis-Related Gene Prognostic Index for Clear Cell Renal Cell Carcinoma

2021 ◽  
Author(s):  
xuexiang Li ◽  
Yarong Song ◽  
Bing Liu ◽  
Liang Chen ◽  
dingheng Lu ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Risk Score ◽  
Immune Checkpoint Inhibitor ◽  
Cox Regression ◽  
Clear Cell ◽  
Checkpoint Inhibitor ◽  
Cell Renal Cell Carcinoma ◽  
Checkpoint Inhibitor Therapy ◽  
Score Model ◽  
Immune Score

Abstract Background: Clear cell renal cell carcinoma (ccRCC), a common pathological subtype of renal cancer with high aggressiveness, has been reported to be associated with chronic inflammation. Pyroptosis, a newly discovered inflammatory form of programmed cell death, can aggravate the inflammatory response. However, the influence of pyroptosis-related genes on ccRCC patient outcomes is yet unknown.Methods: In this study, 43 differentially expressed pyroptosis-related hub genes were identified by analysing The Cancer Genome Atlas–Kidney Renal Clear Cell Carcinoma dataset. The risk-score model was selected using the least absolute shrinkage and selection operator Cox regression and Cox multivariate methods, and all patients were divided into two risk subgroups based on the risk score. Prognostic value of the risk-score model was verified through survival curve, receiver operating characteristic curve and risk curve. Gene ontology and Kyoto Encyclopaedia of Genes and Genomes analyses suggested that the differentially expressed genes between the two subgroups were enriched in immune-mediated categories. Furthermore, the relationship between the risk-score model and ESTIMATE immune score and immunophenoscore was analysed. Finally, Nomogram was constructed based on the results of cox regression analyses. Results: The training cohort and the validation cohort enrolled 346 and 148 ccRCC patients respectively. The risk-score model was constructed by two genes (AIM2 and GSDMB). The area under curve of the ROC curve in two cohorts were both greater than 0.6. The grade and risk score were selected as independent factors and used to construct a nomogram to predict ccRCC patients' survival rate with the c-index of 0.68. Moreover, high-risk score subgroup was associated with a higher immune score and a lower percentage of PBRM1 mutations. The risk score was positively related to the degree of immune infiltration of CD8+ T, T follicular helper, gamma delta T, and regulatory T cells, and patients with a higher risk score were more likely to benefit from immune checkpoint inhibitor therapy. Conclusion: The risk-score model based on pyroptosis-related genes constructed in our study is a promising biomarker to predict the prognosis, molecular and immune characteristics, and immune benefit from immune checkpoint inhibitor therapy in ccRCC patients.

Sign in / Sign up

Export Citation Format

Share Document